Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials

Ting-Rui Han; Wen-Juan Yang; Qing-Hua Tan; Shuai Bai; Huang Zhong; Yang Tai; Huan Tong

doi:10.3389/fmicb.2022.1004911

Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials

Front Microbiol. 2023 Jan 16:13:1004911. doi: 10.3389/fmicb.2022.1004911. eCollection 2022.

Authors

Ting-Rui Han¹, Wen-Juan Yang^{2

3}, Qing-Hua Tan^{2

3}, Shuai Bai², Huang Zhong⁴, Yang Tai³, Huan Tong^{2

3}

Affiliations

¹ West China School of Medicine, Sichuan University, Chengdu, China.
² Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
³ Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
⁴ Department of Gastroenterology, Zigong First People's Hospital, Zigong, China.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut-liver axis in liver disease. We reviewed randomized controlled trials on gut microbiota therapy in NAFLD in this study to evaluate its efficacy and plausibility in NAFLD.

Keywords: antibiotics; fecal microbiota transplantation; gut microbiota; non-alcoholic fatty liver disease; prebiotics; probiotics; randomized clinical trial; synbiotics.

Publication types

Review